Up to now, no vaccine has been developed for COVID-19 treatment. Although many scientists are working for the rapid development of a vaccine to control this pandemic, nonetheless, it will take time. If the vaccine will be developed soon, it will not be available to the entire world instantly since the mass production of the vaccine will take time. In this scenario, we will have to take alternative measures to control the COVID-19 pandemic. These alternative approaches include the stimulation of the immune system to fight against viral infections. Among the different approaches to strengthen the immune system, the use of probiotics is the best one. Probiotics can help the body to fight against COVID-19 directly and indirectly. In this review, we comprehensively discuss the use of probiotics for the prevention and control of COVID-19.

COVID-19 Probiotics Immune stimulation

In Wuhan, China, the World Health Organization (WHO) declared a vague type of pneumonia on the 31^st of December 2019 and it was identified as a public health importance of international concern1, 2. In Central China, Wuhan is known as the most overcrowded city with approximately 11 million residents. Over 27 pneumonia cases of unknown cause were found in Wuhan city with clinical symptoms of cough, fever, dyspnea, and pulmonary infiltrates on tomography3, 4. All patient cases were associated with the Huanan Seafood Wholesale Market, where sales of fish and other kinds of live animals, such as chicken birds, bats, snakes and squirrels, had taken place. The occurrence of cases of severe pneumonia with unknown etiology was thought to be the starting point of a potential epidemic5. Due to the massive movement of people during the Chinese Spring Festival, which potentially fueled the epidemic further, public transport was deferred in Wuhan city and ultimately in all other cities in the Hubei Province to minimize the transmission of infection6.

On 7th January 2020, the Chinese Center for Disease Control conducted a study to identify the etiology through swab samples from the throat. Subsequently, the etiological agent was identified and named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the World Health Organization named the infection as COVID-197. Initially, patients having SARS-CoV-2 infection presented slight symptoms including dry cough, fever, and sore throat. The majority of the cases presented severe clinical signs and symptoms such as organ malfunction, low blood pressure, lung edema, pneumonia, and Acute Respiratory Distress Syndrome (ARDS)8. It is reported that 55.3% of male patients were infected with SARS-CoV-2 with the average age of 50-60 years. Particularly, the old age group required intensive care support due to multiple disease histories including cardiovascular, cerebrovascular, and respiratory disorders9.

Coronaviruses are positive-sense RNA enveloped viruses and their diameter varies from 60 to 140 nm. On the surface, they have spike projections which appear as crown-shaped under electron microscopy and, thus, the virus was named as coronavirus10. Coronavirus belongs to the subfamily Coronavirinae and the family Coronaviridae of the Nidovirales. Four types of genera have been included in the subfamily Coronavirinae such as Alphacoronavirus, Beta-coronavirus, Gamma-coronavirus, and Delta-coronavirus11.

In the past two years, two incidents of the epidemic have occurred in which beta coronavirus was transmitted from animals to humans with dreadful outcomes12. In 2002-2003, the first incidence occurred in the Guangdong Province of China in which novel beta coronavirus was transmitted from bats to humans with the aid of intermediate hosts like palm civet cats13. This novel beta-coronavirus was known to cause severe acute respiratory syndrome which affected thousands of people in China and Hong Kong. In Saudi Arabia in 2012, middle east respiratory syndrome (MERS) coronavirus was identified from bat and dromedary camels as their intermediate host and it also affected hundreds of people at that time with a fatality rate of 34%14. Currently, the world is dealing with another pandemic caused by the spread of coronavirus originating from bats and spreading in the human population which is named COVID-19 15. This review is about the recent and ongoing pandemic which started in China on 31^st December 2019. The review highlights the main source of viral infection, as well as its prevalence, analysis, pathogenesis, and ways to control the outbreak; moreover, the role of probiotics for the control of COVID-19 will be a predominant discussion.

The WHO recognized that the COVID-19 outburst emerged from the meat of wild animals sold in the ‘wet markets’ of South China. Recently, it was reported that this disease was first identified in Wuhan China on 31^st of December 201912. This virus spread throughout China after just a few weeks of emergence. Then, it spread within a month to various other countries, including Germany, Italy, and the United States of America16.

The incidence curve can be roughly grouped into 3 phases: 17

On February 10^th, 2020, in China, the percentage of infected people were starting to decrease from 98.3% to 11%, with the success being owed to the lock down of Wuhan. Contrary to this, the infected cases became elevated in other countries- from 0.67% to 91% in the similar period31, 32. According to reports33, 34, the worldwide prevalence of cases until May 2020 are shown in Table 1. The total of COVID-19 cases reported and deaths reported, according to the data analysis reports up to May 2020, are shown in Figure 1 35, 36.

Figure 1 Table 1

Date	China	Other countries	No. of Infected countries
1-March-20	310	1946	15
12-March-20	5473	10,66	19
28-March-20	15743	103,273	24
1-April-20	78234	212, 309	25
14-April-20	31157	214, 545	26
22-April-20	76554	295, 300	27
30-April-20	69662	297, 886	47
4-May-20	70366	299, 998	77
10-May-20	70829	425, 357	110
16-May-20	798123	792, 450	161
22-May-20	790234	701, 222	189
26-May-20	820563	891, 732	198
30-May-20	83225	877, 610	210

Since 31^st December 2019 and as of 18^th October 2020, 39,774,852 cases of COVID-19 (in accordance with the applied case definitions and testing strategies in the affected countries) have been reported, including 1,110,902 deaths.

Cases have been reported35, 36:

Africa: 1,638,567 cases; the five countries reporting most cases are South Africa (702,131), Morocco (170,911), Egypt (105,297), Ethiopia (88,434) and Nigeria (61,307).

Asia: 12,349,067 cases; the five countries reporting most cases are India (7,494,551), Iran (526,490), Iraq (423,524), Bangladesh (387,295) and Indonesia (357,762).

America: 18,773,414 cases; the five countries reporting most cases are United States (8,106,752), Brazil (5,224,362), Argentina (979,106), Colombia (952,371) and Peru (865,549).

Europe: 6,976,052 cases; the five countries reporting most cases are Russia (1,384,235), Spain (936,560), France (867,197), United Kingdom (705,428) and Italy (402,536).

Oceania: 37,056 cases; the five countries reporting most cases are Australia (27,383), French Polynesia (3,797), Guam (3,617), New Zealand (1,530) and Papua New Guinea (581).

Other: 696 cases have been reported from an international conveyance in Japan.

Deaths have been reported35, 36:

Africa: 39,554 deaths; the five countries reporting most deaths are South Africa (18,408), Egypt (6,109), Morocco (2,878), Algeria (1,846) and Ethiopia (1,346).

Asia: 221,299 deaths; the five countries reporting most deaths are India (114,031), Iran (30,123), Indonesia (12,431), Iraq (10,198) and Turkey (9,224).

America: 608,716 deaths; the five countries reporting most deaths are United States (219,289), Brazil (153,675), Mexico (86,059), Peru (33,702) and Colombia (28,803).

Europe: 240,306 deaths; the five countries reporting most deaths are United Kingdom (43,579), Italy (36,474), Spain (33,775), France (33,392) and Russia (24,002).

Oceania: 1,020 deaths; the five countries reporting most deaths are Australia (904), Guam (66), New Zealand (25), French Polynesia (14) and Papua New Guinea (7).

Other: 7 deaths have been reported from an international conveyance in Japan.

The primary assessment of COVID-19 spreading revealed that the basic reproductive number (R₀) of COVID-19 was evaluated to be 1.4-3.9, the R_o of SARS-CoV was 2.3-3.7, and the R_o of MERS-CoV was 0.50-0.92. It should be noted that R_o evaluation may fluctuate upon various social behavioral and environmental factors, and thus must be deduced with care37, 38.

Coronavirus consists of particular genes in the ORF1 downstream region that encodes for proteins involved in the production of nucleocapsid, spikes, and replication of virus. Spikes are made up of glycoproteins and are present on the outer surface of coronavirus39, 40. These spikes help in the attachment and penetration of the virus in the host cell (Figure 2). Among viruses, the receptor-binding domain (RBD) is loosely attached; hence, due to this RBD, coronavirus may infect more than one host. In the case of COVID-19, aminopeptidase and carbohydrates are used as the primary receptor for penetration of virus into the human host, whereas SARS-CoV and MERS-CoV recognize exopeptidase41, 42. The mechanism of virus penetration depends upon cellular proteases, such as human airway trypsin-like proteases (HAT) and transmembrane protease serine 2 (TMPS2), as well as cathepsins that split the spike proteins and create further penetration changes. MERS-CoV requires dipeptidyl peptidase 4 (DPP4), whereas SARS-CoV employs angiotensin-converting enzyme 2 (ACE2) as the primary receptor43.

Figure 2

SARS-CoV-2 has a typical structure with spikes (protein) and also expresses other polyproteins, nucleoproteins, and membrane proteins (like RNA polymerase, 3- chymotrypsin-like protease, papain-like protease, helicase, and glycoproteins)42. The spike protein is comprised of a 3D configuration in the RBD region to sustain the van der Waals forces. In SAS-CoV-2, the 394-glutamine residue in the RBD region is recognized by the critical lysine 31 residue on the human ACE2 receptor44, 45. The complete pathogenicity mechanism of SARS-CoV-2, from attachment to replication, is described in Figure 3.

Figure 3

The SARS-CoV-2 genome homology has identified over 80% of the SARS-CoV. Four structural genes encode structural proteins which entail Spike (S), Membrane (M), and nucleocapsid (N) proteins. In SARS-CoV-2, the orf1ab gene is known as the bulkiest gene, which encodes pp1ab and 15 non-structural proteins (nsp)3. The orf1a gene encodes pp1a proteins which are also comprised of 10 nsp. Prior studies have indicated a noticeable difference in SARS-CoV and SARS-CoV-2, which includes the absence of 8a protein and variation in the amino acid numbers in 8b and 3c protein of SARS-CoV-2, as shown in Figure 4. It is also noted that spike proteins of coronavirus isolated from Wuhan is modified through homologous recombination2, 1. Additionally, it has been noted that the SARS-CoV-2 also uses the same ACE2 receptor for the attachment of the virus to the host cell, which was previously used by the SARS-CoV. A single mutation in the spike proteins of SARS-CoV-2 may have considerably increased its attachment affinity for ACE25, 4.

Figure 4

The sign and symptoms of COVID-19 infection have seemed to appear after 5-9 days, which is the incubation period. The duration from the appearance of symptoms to death has ranged from 7 to 42 days. This duration highly depends on the patient's age and the condition of the patient's immunity. This period is shorter in those patients who are less than 60 years old7, 6. Primarily, the person suffers from a runny nose and sore throat for 2-3 days, followed by an infrequent degree of fever while further symptoms have also included headache, hemoptysis, diarrhea, sputum production, lymphopenia and dyspnea8. Tomography of the infected patients has revealed pneumonia, acute respiratory syndrome, acute cardiac infection, and RNAemia, which have led to mortality. In some patients, multiple pulmonary nodules were detected in the subpleural area of both lungs which stimulated both localized and systemic immune responses that led to increased infection9. Unfortunately, treatment with interferon intake showed no promising effect and, in fact, worsened the situation of the patients by progressing pulmonary opacities, as shown in Figure 5.

Figure 5

It is noteworthy that there are resemblances in the signs and symptoms of COVID-19 and beta-coronavirus; these signs/symptoms include dry cough, fever, dyspnea, and hazy bilateral opacity on chest tomography10. Furthermore, some clinical features have been observed in COVID-19 infection, such as upper respiratory tract infections, rhinorrhea, sneezing, and sore throat10. However, chest tomography of the patients has shown infiltrates in the upper lobe of the lungs that are linked with increasing dyspnea with hypoxemia. Significantly, COVID-19 infected patients have developed gastrointestinal tract infections such as diarrhea, while fewer cases of SARS-CoV and MERS-CoV had GI infections12. Thus, it is significant to develop methods for the identification of different routes of transmission like fecal and urine samples and immediate examinations in order to develop strategies to minimize viral transmission and to develop medicines to minimize the risk of disease.

The key evaluation of the clinical signs and symptoms of COVID-19 infection was declared in a presentation in Wuhan city. However, despite the continually prolonged and abstruse situation of the pandemic, the Chinese and American Centers for Disease Control (CDC) introduced as prevention various surveys and reagents which were generated for aiding the recognition of several infections in the clinical samples13. Majumder and Mandl (2020) concluded that several investigators used real-time PCR methods to test for COVID-19. The RT-PCR mixture contains an open reading frame (Orf), envelope (E), nucleocapsid (N), and RNA-subordinate RNA polymerase (RdRp)14. On the 4^th of February 2020 a significant step was undertaken by the United States Food and Drug Admiration (FDA) when the agency provided the authorization of the US CDC’s COVID-19 detection kit (via PCR methodology) and also invested in the CDC licensed research facilities to perform the detection testing. Currently, 115 CDC research labs are operating in the US, with approximately 191 licensed labs worldwide 15. Within 2-14 days of exposure, symptoms of fever, cough, and breathing problems occur, followed by continuous cardiac pain and discomfort, experience of misperception, and bluish lips or face; all these are believed to be signs of COVID-1916. Despite the fact that there is no logical history of appearance of symptoms, a COVID-19 case should be considered as having 3 clinical symptoms, such as fever, cough, and breathing problems. In the description of the 5^th clinical sign, computed tomography (CT) of chest scan can recognize viral pneumonia, which is regarded as a confirmation of COVID-19 infection28. It is interesting to note that WHO did not allow the chest computed tomography without the RT-PCR test until February 17^th, 2020. Furthermore, novel coronavirus pneumonia diagnosis and treatment program of 2019 has expelled out the clinical analysis for the detection of COVID-19. As showed from the clinical symptoms, confirmed patients are grouped into mellow, mild, severe, and uncomplicated cases17.

Figure 6

Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing COVID-19 pandemic. The herculean effort means that a fast-tracked vaccine could come to market anywhere from the end of 2020 to the middle of 202146. To date just two corona virus vaccines has approved sputnik V-formally known as Gam COVID-Vav and developed by Gamaleya research institute Moscow. Experts have raised considerable concerns about the vaccine safety and efficacy given it has not entered the phase 3 clinical trials. A second vaccine in Russia EpiVacCorona has also been granted regulatory approval, also without entering phase 3 clinical trials46.

There are several problems in evading the infection caused by COVID-19 in various areas, such as clinically sensitive cases or atypical introductions. The CDC has proposed that the medical staff should use personal protective equipment (PPE), and follow the standard protocols of safety measures of airborne pathogens, including covering the eye18. It has been suggested that medical service providers should wear protective attire, gloves, N95 mask, and air removal respirators19. The CDC proposed the manifestation of airborne infection detention rooms that should be reserved for COVID-19 patients. Furthermore, the CDC recommends the implementation of environmental pollution controls, by assuring proper techniques of ecological cleaning and purification methods. Designing control usages, such as physical limitations, used curtains between two patients in shared spaces, air filters for inappropriate air route, and quarantining, could reduce the occurrence of COVID-19 cases8. Safety and health authorities had made policies to help the forest all the onset and spread of COVID-19, such as hand washing for at least 20 seconds after every half an hour and use of liquor sanitizes having a minimum of 65% liquor. Prevention of touching nose, eyes, face with grubby hands, as well as avoidance of close interaction with other persons, are also critical20.

Antibodies from COVID-infected persons can be an ultimate solution in preventing and eliminating COVID-19. Still, no booster of the immune system against SARS-CoV-2 is available. Vaccines are now being developed for immunization. The National Institutes of Health (NIH) is on phase 1 to develop a mRNA antibody; it is currently in its initial stages (March 2020). Due to the deficiency of an appropriate remedy, an ideal action to control the SARS-CoV-2 disease is to reduce the risk factor of this outbreak21. Likewise, safety measures should be important in the prevention of COVID-19; these include improvement of health hygiene, use of medical masks, proper rest, social separation, and staying at home in well-aerated rooms. Until the development of vaccines, this pandemic can be controlled by improving the immune status of the cases in different ways, such as the use of probiotics.

Despite policies such as safety measures, isolation, and social separation to limit COVID-19 infection, and despite the fact these policies have been quickly shared globally to aid in the medical management of COVID-19, there is still much threat and concern about infection. Even though the discovery of medical interventions for COVID is rampant and ongoing, such treatments like vaccines will not be available until possibly late in the coming year. Thus, more prophylactic approaches are necessary22. A variety of symptoms have been identified which are caused by COVID-19, including flu-like systems, pneumonia, severe respiratory infection, and failure of body organs. Therefore, in the spread of SARS-CoV-2, air droplets are the main source and the gastrointestinal tract may also be involved in the pathogenesis of coronavirus. RNA of SARS-CoV-2 has also been found in the patients’ gut and fecal samples, and in the sewage pipelines. SARS-CoV-2 can infect intestinal absorptive cells, thus acting as a carrier for COVID-19 23. Certainly, from China, large clinical data have revealed that gut infection is common in coronavirus and contributes to the severity of disease. Probiotics are vital microorganisms that when consumed at a sufficient dose, can confer a beneficial effect in the host. Medical data have shown that particular strains of probiotics facilitate the prevention of viral and bacterial infections, such as sepsis, gastroenteritis, and respiratory tract syndrome24. The purpose of discussing probiotics in the prevention of bacterial and viral infections is founded in science and medical data, although not directly on the etiological agent of this outbreak.

Probiotics can control drug-associated diarrhea and gastrointestinal tract infection, and control other sites of infections like respiratory tract infections and sepsis. For evidence-based medicines, the gold standard would be the meta-analysis26. In one investigation on approximately 9,000 newborns counted in randomized controlled trials, the mother’s intake of probiotics through the gastrointestinal tract could decrease necrotizing enterocolitis, nosocomial sepsis, and mortality risk25. A well-organized randomized controlled trial in India consisting of more than 5,000 infants treated with lactobacillus plantarum strain associated with prebiotics showed a declining level of sepsis and lower respiratory tract infections27. Viruses are the main factor causing upper respiratory tract infections. In the prevention of upper respiratory tract infections, the beneficial effect of probiotics has been confirmed. Multiple studies of 13 randomized controlled trials have been conducted which contains 4,230 youngsters and kids who were given probiotics28; there was a 2-fold decrease in risk of lower and upper respiratory tract infections and a lower but noteworthy decrease in the severity of disease in the carrier patients. Moreover, there was a randomized, double-blinded placebo-controlled study with 523 youngsters who were given lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, and Bifidobacterium bifidum MF 20/5, with some minerals and vitamins. The results showed lower flu periods and also a reduction in fever days29. A randomized controlled trial containing 93 newborns were given galacto-oligosaccharides and polydextrose prebiotic combination (1:1) and Lactobacillus rhamnosus GG in 3 to 60 days. Treatment reduced by 2- to 3-fold the occurrence of respiratory tract viral infections as compared to the placebo-control. The occurrence of rhinovirus-related events which include 85% of all respiratory tract infection cases in this study was also highly decreased with the consumption of prebiotics and probiotics. Lactobacillus brevis has also demonstrated promising results in a study of 1,692 school kids and strongly reduced the occurrence of influenza respiratory tract infections30. In studies, the outbreak has distressed the youngsters moreso than kids, but Bifidobacterium longum has been documented in a randomized controlled trial of 28 adults and has also shown promising results. Moreover, many probiotics are being selected from lactic acid bacteria that are commonly found in the upper respiratory tract of healthy persons, and most of the probiotic strains are listed in the prevention of persistent otitis media 31. Thus, it can be concluded that probiotics have a valid contribution in slowing down the incidents of coronavirus outbreak. Apart from use in viral infections, probiotics can also help in reducing bacterial infections like lower respiratory tract infections in adults. Multiple experimental data have been obtained from a randomized controlled trial containing 2,000 infected patients of ventilator-related pneumonia. In this study, the results from more than 1,800 adults showed recovery and reduction of incidents32. However, evidence of lower quality and contradictory results in various trials warrants further investigations with well-organized randomized and controlled design. It must be noted that not all probiotics are involved in decreasing the risk of respiratory tract infections, even the probiotics with gastrointestinal benefits. For example, Bifidobacterium animalis and Lactobacillus rhamnosus might contribute to intestinal aid but do not decrease the virus number in the nasopharynx33. Examples of probiotic products that could be beneficial in all aspects depend on their accessibility in a given country, as shown in Table 2.

Table 2

Probiotics	Function of probiotics	Administration duration	References
Lactobacillus casei DN-114 001; DanActive/Actimel Fermented drink, Danone	Decrease occurrence and extent of RTIs	daily used in the pandemic duration	45
Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, and B. bifidum MF 20/5; Tribion harmonis, Merck	reduced extent and acuteness of flu-type infection	daily used in the pandemic duration	3
Lactobacillus rhamnosus GG; Culturelle or other brand names	For healthy digestion and gut barrier strength, and anticipation of viral RTI.	daily used one capsule in the pandemic duration	4
Lactobacillus plantarum DR7; Malaysia	immune stimulation lowering the upper RTI,	daily used 2g sachet in the pandemic duration	9
Bifidobacterium breve Yakult, and Lactobacillus casei Shirota; available as fermented drinks	reduce the prevalence of ventilator-associated pneumonia	daily used in the pandemic duration	35
Bifidobacterium longum BB536; Morinaga, and sold in many formulations	stimulate innate immune response and, protects from influenza,	daily used in the pandemic duration	36
Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, L. paracasei ssp. paracasei 19, L. plantarum 2,362 plus inulin, oat bran, pectin, and resistant starch; Medipharm, Sweden	To decrease the SIRS infection rate, sepsis, duration of stay in the hospitals especially on ventilators, and rate of mortality	For COVID-19 patients	36
A probiotics list accessible in Canada for several health problems: www.probioticchart.ca A probiotics list accessible in the USA for several health problems: www.usprobioticguide.com
We must highlight that either of these has not been verified or confirmed to have effective against COVID-19, nor are they tested for the therapy and treatments for s this circumstance

Studies that discuss success of probiotics in clinical trials have indicated parameters such as improvement of the epithelial barrier of intestines, competition with disease-causing agents for nutrients, attachment on the epithelium wall of intestines, production of anti-pathogen elements, and enhancement of the immune system of the host34. A randomized controlled study design of 63 newborns who received enteral nutrition along with Bifidobacterium bifidum and Streptococcus thermophilus showed a decline in diarrheal incidents and reduction of rotavirus shedding, as demonstrated by results obtained from the meta-analysis. These findings indicate an interruption in the entry of the virus into the cell and inhibition of viral replication in the host intestine35. Therefore, this system may contribute to the reduction of coronavirus invasion through the gastrointestinal tract because probiotics are not taken in through the respiratory tract.

Consequently, at this site, direct prevention of viruses might not be possible. It is also reported that the microbiota is also found in the lungs; gut-lung association has been discussed whereby microbe-to-microbe and host-to-microbe immune collaborations might stimulate the progression of respiratory infections. Influenza-type infections are related to the discrepancy of microbial groups of the gastrointestinal and respiratory tracts36. This dysbacteriosis might change the functions of the immune system and prompt secondary bacterial infection. As studies from China have shown, COVID-19 may be accompanying intestinal dysbacteriosis, thereby causing severe infection; restoration of gut homeostasis may be helped through probiotic strains. It is reasonable that probiotic strains, when orally administered, could stimulate gut-lung association and some strains can migrate from the gut to other nearer sites, like breast, to medicate mastitis4. The microbiota of the gut has a significant effect on the host immune response, systemically, and on immune reactions at nearby mucosal sites, such as lung. Consumption of particular bifidobacterial and lactobacilli strains can have a positive effect on the clearance of influenza virus from the respiratory tract.

Certain strains of probiotic have enhanced interferon type I levels, elevating the number and function of antigen-presenting cells, natural killer cells and T cells, as well as increasing the level of particular antibodies at the systemic and mucosal sites47. There is also proof that strains of probiotic can amend the stability among pro-inflammatory and immunoregulatory cytokines that permit the clearance of viruses. This could be mostly appropriate to avert the acute respiratory distress syndrome, a major impediment of COVID-19. A randomized controlled design includes teenagers who exhibit suppression of plasma pro-inflammatory cytokines, such as IFN-γ and TNF-α, with the use of Lactobacillus DR7. Another trial of young adults showed improvement in anti-inflammatory cytokines, like IL-4 and IL-10, and reduction in the peroxidation of plasma cells and oxidative stress levels37. Certain storms of cytokines might develop in patients with COVID-19, and this modulation type might prove to be very significant. The method in which strains of probiotic are orally consumed would contribute to the emergence of the immune response from the intestines, a crucial point of the host defenses. Therefore, strains of probiotics are known to improve the firmness of tight junctions; for instance, they could act as fuel for colonocytes which could tentatively reduce the invasion of SARS-CoV-2 by increasing the level of butyrate. Probiotic strains have also been demonstrated to exert anti-viral activity, as shown in experimental and medical studies38. However, none of these mechanisms and effects have been verified on SARS-CoV-2. This approach should not be refused, particularly when probiotic strains have been positively tested against other strains of coronavirus. Moreover, patients are also currently affected from secondary bacterial infections. A prior study showed that mice with pulmonary infection due to Pseudomonas aeruginosa and Staphylococcus aureus, when orally administered with probiotic strains of Lactobacillus acidophilus, demonstrated a decrease in the bacterial burden from the lungs and a reduction in the chances of lung impairment and systemic infection39.